Skip to main content
Premium Trial:

Request an Annual Quote

GE Healthcare's Revenues Slide 3 Percent in Q4

NEW YORK (GenomeWeb News) – GE Healthcare today reported that fourth-quarter revenues for its GE Healthcare business, which includes the firm's tools for molecular research, declined 3 percent year over year.

GE Healthcare's revenues were $4.8 billion for the quarter compared to $5 billion in Q4 of 2007. The unit's profit dropped 9 percent to $942 million from $1 billion year over year.

For full-year 2008, GE Healthcare generated revenues of $17.4 billion, up 2 percent over 2007 revenues of $17 billion. Its full-year profit declined 7 percent to $2.9 billion from $3.1 billion.

Fiscal 2008 revenues for the parent company, General Electric, were $182.5 billion, up 6 percent from $172.5 billion for 2007. The firm's net earnings attributable to common shareowners were $17.3 billion, or $1.72 per share, down 22 percent from $22.2 billion, or $2.18 per share, for 2007.

GE Healthcare is one component of GE's Technology Infrastructure business segment, which also includes the conglomerate's Aviation, Enterprise Solutions, and Transportation units.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.